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Abstract 
BACKGROUND: Tyrosine kinase inhibitors (TKIs) have been introduced for the treatment of lung cancer, 
improving progression-free survival, objective response rate, and quality of life. However, TKIs can lead to 
cutaneous toxicities, including papulopustular rash, xerosis, paronychia with/without pyogenic granulomas, scalp 
disorders, facial hair and/or eyelash growth.  
AIM: In this study, we describe retrospectively all cases of mucocutaneous side effects in patients with lung 
cancer under TKIs referring to our outpatient for the skin care of oncological patients. 
METHODS: We included patients referring from January 2016 to January 2018 affected by lung cancer and under 
TKIs. We collected data about the clinical exam, clinical photography, dermoscopy, histology and direct 
microscopic examination for each patient and we performed retrospectively descriptive analyses to assess 
whether a specific TKIs is linked significantly to particular cutaneous toxicity.  
RESULTS: The majority of skin toxicities were due to afatinib, and the most common skin reaction was rash. We 
selected 60 patients with skin reactions, treated by TKIs for lung cancer. The majority of skin toxicities were due to 
afatinib (47/102 adverse reactions) and erlotinib (39/102). The most common skin reaction was rash (63% of 
patients), followed by xerosis (30%) and granulomas (30%). There was no significant relationship between a 
specific type of cutaneous reaction and specific EGFRi except for granulomas, developed more frequently in 
patients under afatinib (p < 0.05). 
CONCLUSION: Most of our patients (63%) developed a cutaneous rash under TKIs. Most commonly afatinib was 
the drug involved, although it wasn’t the most used EGFRi. Moreover, we noticed a significant correlation between 
afatinib therapy and appearance of granulomas. 
 
 
 
 
 
 
Introduction 
 
According to WHO data, lung cancer is the 
most common cause of cancer mortality (1.69 million 
deaths) [1]. 
The introduction of new therapeutic agents, 
with a different mechanism of action respect to 
traditional chemotherapy, led to a dramatic shift in 
patients’ management [2]. In the last decades, several 
chemotherapeutic agents including target therapy 
have been introduced in the guidelines, impressively 
improving the survival rate of patients with lung 
cancer. Nowadays tyrosine kinase inhibitors (TKIs) 
have transformed the treatment of lung cancer, 
improving progression-free survival, objective 
response rate, and quality of life [3]. To date, three 
generations of TKIs are available: the first one 
includes gefitinib, erlotinib and icotinib; the second 
one afatinib, neratinib and dacomitinib; and the third 
one osimertinib, rociletinib and olmutinib [2]. 
However, TKIs can lead to several side 
effects. Skin toxicities are the most common and 
earliest reported. [4] Among them, papulopustular 
rash, xerosis, paronychia with/without pyogenic 
granulomas, scalp disorders, facial hair and/or 
eyelash growth frequently occur [5].  
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Studies suggest that cutaneous specificity for 
TKIs -associated adverse reactions might be due to 
the strong expression of EGFR [6] and to the multiple 
regulatory functions of EGFR/ligand system in the 
epidermis [7]. 
Currently, no studies exclusively on 
cutaneous toxicity of EGFRi in patients affected by 
lung cancer are available in recent literature. 
Our study aims to describe retrospectively all 
cases of mucocutaneous side effects in patients with 
lung cancer under TKIs referring to our outpatient for 
the skin care of oncological patients. 
 
 
Material and Methods 
 
From January 2016 to January 2018, 263 
patients referred to our outpatient for cutaneous side 
effects from oncological therapy. Seventy-six patients 
had lung cancer, and 60 of them were treated by TKIs 
(25 erlotinib, 22 afatinib, 10 gefitinib and 3 
osimertinib). We excluded patients already suffering 
from mucocutaneous symptoms at the beginning of 
chemotherapy. All data were collected from the 
computerised database of our department.  
We collected data about the clinical exam, 
clinical photography, dermoscopy, histology and direct 
microscopic examination results for each patient.  
The analysed data also included personal and 
clinical characteristics such as gender, age, type of 
lung cancer, therapeutic agent, site and clinical 
presentation of skin reaction. 
We performed retrospective descriptive 
analyses, and we classified data by patients’ clinical 
characteristics, types of lung cancer, treatment and 
adverse reactions. The study was conducted by 
ethical guidelines and providing informed consent 
from the subjects enrolled. 
 
Statistical analysis 
We carried out statistical analysis to assess 
whether a specific EGFRi is linked significantly to 
particular cutaneous toxicity. We excluded patients 
treated with osimertinib because of the insufficient 
sample size. 
Categorical variables were reported as 
absolute number and percentage and compared using 
the exact chi-square test. A two-tailed P-value < 0.05 
was considered significant. Data were analysed using 
SAS version 9.4 (SAS Inc, Cary, NC).  
 
 
Results 
 
We selected 60 treated by TKIs of 76 patients 
with lung cancer and skin reactions.  
A group of 31/60 were males (51.67%), and 
29/60 (48.33%) were females. Patients aged from 41 
to 80 years (mean age 64.60 ± 10.85 DS). The lung 
cancer type diagnosed was: 41/60 (68.33%) 
adenocarcinoma, 6/60 (10.00%) squamous cell 
carcinoma, 6/60 (10.00%) Small Cell Lung cancer 
(SCLC) and in 7/60 (11.67%) patients the lung cancer 
type was not specified nor included in the previous 
categories. 
The most frequent TKIs were erlotinib (25/60, 
41.67%) followed by afatinib (22/60, 36.66%) Table 1. 
Table 1: Characteristics of patients included in our analysis 
Sex Mean age (years ± DS) Cancer type Treatment 
31 M (51.67%) 64.60 ± 10.85 41 adenocarcinoma 25 erlotinib 
29 F (48.33%)  6 squamous cell carcinoma 22 afatinib 
  6 SCLC 11 gefitinib 
  7 other or not specified 2 osimertinib 
 
The majority of skin toxicities were due to, in 
order of frequency: afatinib (47 reported adverse 
reactions), erlotinib (39), gefitinib (13) and osimertinib 
(3). The most common skin reaction was rash (63% of 
patients), followed by xerosis (30%), granuloma 
(30%), mucositis (18%), psoriasis (8%), fingertips 
fissures (7%), itching (5%). Alopecia (5%), hand-foot 
syndrome (2%), and trichomegaly (2%) (Figure 1). 
 
Figure 1: Papulo-pustular rash under EGFRi in its typical 
localization (trunk and head) 
 
Data and frequency distribution are reported 
in Table 2. 
Table 2: Frequency of adverse cutaneous events related to 
TKIs’ administration 
 Erlotinib 
25 
patients 
Afatinib 
22 
patients 
Gefitinib 
11 
patients 
Osimertinib 2 
patients 
Total 
ADR/reaction 
% ADR/patient 
Rash 14 (56%) 17 (77%) 6 (55%) 1 (50%) 38 63% 
Xerosis 7 (28%) 7 (32%) 4 (36%) 0 (0%) 18 30% 
Granuloma 6 (24%) 11 (50%) 1 (9%) 0 (0%) 18 30% 
Psoriasis 3 (12%) 2 (9%) 0 (0%) 0 (0%) 5 8% 
Mucositis 2 (8%) 7 (32%) 1 (9%) 1 (50%) 11 18% 
Pruritus 1 (4%) 1 (5%) 0 (0%) 1 (50%) 3 5% 
Fingertips fissures 2 (8%) 2 (9%) 0 (0%) 0 (0%) 4 7% 
Alopecia 3 (12%) 0 (0%) 0 (0%) 0 (0%) 3 5% 
Hand-foot 
syndrome 
0 (0%) 0 (0%) 1 (9%) 0 (0%) 1 2% 
Trigomegaly 1 (4%) 0 (0%) 0 (0%) 0 (0%) 1 2% 
Total ADR/drug 39 47 13 3   
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Statistical data revealed that there was no 
significant relationship between a specific type of 
cutaneous reaction and specific EGFRi except for 
granulomas, appearing significantly more frequently in 
patients under afatinib (p < 0.05). 
Statistical data are reported on Table 3. 
Table 3: Statistical analysis 
 Rash Xerosis Granuloma Psoriasis Mucositis Pruritus Fingertips 
fissures 
Alopecia Hand-Foot 
Syndrome 
Trichomegaly 
Erlotinib 
25 
patients 
14 7 6 3 2 1 2 3 0 1 
56% 28% 24% 12% 8% 4% 8% 12% 0% 4% 
Afatinib 
22 
patients 
17 7 11 2 7 1 2 0 0 0 
77% 32% 50% 9% 32% 5% 9% 0% 0% 0% 
Gefitinib 
11 
patients 
6 4 1 0 1 0 0 0 1 0 
55% 36% 9% 0% 9% 0% 0% 0% 9% 0% 
p-value 0,268 0,932 0,037 0,620 0,076 0,999 0,679 0,214 0,190 0,999 
 
 
 
Discussion 
 
In our study, the rash was the most common 
dermatological side effects reported (38 patients), 
followed by xerosis (18), granuloma (18), mucositis 
(11), psoriasis (5). Our data showed that only a few 
patients complaint of fingertips fissures (4), pruritus 
(3), alopecia (3). Only one patient developed hand-
foot syndrome and another one trichomegaly. 
The majority of skin toxicities were due to 
afatinib (47 reported adverse reactions), erlotinib (39), 
gefitinib (13) and osimertinib (3).  
Afatinib was the drug causing more adverse 
reactions although it wasn’t the most used therapy in 
our patient’s sample, confirming Derrick Chen-Wee 
Aw et al. review data [8]. 
In our experience, no statistical difference 
linking a type of cutaneous reaction and specific 
EGFRi were observed except for granulomas. 
The majority of anti-cancer drugs can induce 
rash because they act on rapidly growing cells and 
hence the skin, but also hair follicles and nail matrix. 
TKIs may interfere in the epidermal structure, 
antimicrobial and inflammatory response, leading to 
dysfunction of normal epidermal barrier and 
dysregulated cytokines patterns [4]. 
A papulopustular eruption is the most frequent 
side effect of anti-EGFR drugs reported in the 
literature. The eruption may be asymptomatic or 
accompanied by pruritus, and it tends to improve over 
time despite the continuation of therapy. It is generally 
distributed in the seborrheic areas, where EGFR is 
more expressed [9]. 
The incidence of rash from TKIs observed in 
our study is similar to those of several clinical studies: 
it is more frequent in first or second generation TKIs 
(44.73% of rash due to afatinib, 36.84% in erlotinib, 
15.78% in gefitinib), when compared with third-
generation TKI treatment (2.63% in osimertinib) [9], 
[10]. 
As already reported by Derrick Chen-Wee Aw 
et al., our study confirms that afatinib causes rash 
more frequently than erlotinib, gefitinib and osimertinib 
[8], [11]. We only had two patients under osimertinib 
therapy, and one of them developed a rash (50% of 
total patients), but we cannot conclude that 
osimertinib causes rash as frequently as first or 
second generation TKIs since our data were 
conducted on a few numbers of patients. 
In our study, we observed xerosis in 18 
patients (7 afatinib and erlotinib, 4 gefitinib). 
Comparing to Derrick Chen-Wee Aw et al., we didn’t 
find xerosis in the two patients treated with 
osimertinib, but we cannot consider our percentage 
statistically significative for the limited number of 
patients. The rate of body surface area involved can 
be variable like also the time of onset that can variate 
from 15 days to 60 days [12]. 
Xerosis, also known as xeroderma or dry skin, 
can occur independently or associated with other 
adverse reactions, particularly pruritus [13]. 
In our study, pruritus was found in three 
patients (1 afatinib, 1 erlotinib and 1 osimertinib), but 
no patient treated with gefitinib complaint of itching. 
Our results disagree partially with published literature 
since we didn’t observe gefitinib-induced pruritus [8]. 
A unique common site of xerosis is the 
fingertips, especially in patients treated with EGFR 
inhibitors. Dry fingertips commonly prove in pulpitis 
with painful fissures [9]. In literature, the incidence is 
18-25% and the onset time is around 30-60 days [12]. 
In our study, fingertips xerosis with fissures was seen 
in 4 cases, two treated with afatinib and two with 
erlotinib, in agreement with already reported severe 
cases of pulpitis sicca and painful rhagades [8]. 
From 4% through 56.8% of patients under TKI 
can present nails changes, including paronychia, 
painful fissures, swelling, and noninfectious 
granuloma [12], [14]. In our experience, we have 
reported granulomas in 18 patients, and we found 
that, together with xerosis, the periungual involvement 
is the second most frequent adverse reaction in 
patients under TKIs. Our statistical data show that 
afatinib causes more frequently granulomas. 
Psoriasis, both with diffuse or localised 
involvement of the skin, has been often reported in 
literature during anti-cancer treatment. 
We observed psoriasis in two patients treated 
with afatinib and in three treated with erlotinib; all of 
these patients were affected in the scalp area. In 
literature, there are some contrasting data: there are 
case reports that describe the positive effect of EGFR 
inhibitors in psoriasis. Overbeck presented cases of 
patients with psoriasis treated with tyrosine kinase 
inhibitors; instead, Zorzou observed that psoriasis 
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recurred after treatment with anti-EGFR [15], [16]. 
Mucositis has also been reported with TKIs, 
more frequently with the second generation of TKIs 
than the first one. Incidence of mucositis induced by 
afatinib varies from 29 to 64%, while mucositis 
induced by erlotinib and gefitinib ranges between 8 
and 20% and 19 to 24%, respectively [17]. We 
observed 11 cases (7 afatinib, 2 erlotinib, 1 gefitinib 
and osimertinib) and our results confirm that mucositis 
is more frequently reported with second-generation 
TKIs than the others.  
TKIs can induce hair changes such as hair 
loss (scarring or non-scarring alopecia), scalp 
inflammation or hirsutism including hair rigidity and 
curling, trichomegaly and facial hypertrichosis [8]. In 
literature, it was reported that TKIs cause androgen-
like frontal alopecia with progressive growth of facial 
hair and eyelashes, more evident in female patients 
[18], [9]. In our study, alopecia has been reported in 
three female patients treated with erlotinib, and one of 
them also showed trichomegaly of the malar region.  
Hand-foot syndrome (HFS) or 
Erythrodysesthesia by TKi has been rarely reported in 
the literature [19], [20]. In our study, this reaction was 
found in only one patient treated with gefitinib and not 
exposed to precedent therapy, contrary to ‘recall 
reactions’ which Razis et al., consider in patients 
previously treated with liposomal doxorubicin and then 
with gefitinib [19]. 
Pigmentation disorders (hypo- and 
hyperpigmentation) [21] photosensitivity and also 
telangiectasia [22] have been reported, but, 
hereinbefore, we didn’t find these dermatologic 
toxicities in our patient sample. 
 
Limitations of the study 
The main limitation of our study was the 
limited sample size that leads us to exclude 
osimertinib in the statistical analysis. Moreover, we 
cannot conclude completely that there is no 
association between type of EGFRi and skin 
reactions, but it’s a good start point of view for future 
guidelines. Future studies should include a higher 
number of patients treated with different EGFRi. 
We can conclude that 63% of our patients 
presented rash, most commonly those treated by 
afatinib, although it wasn’t the most used EGFRi. 
Moreover, we noticed a significant correlation only 
between afatinib therapy and appearance of 
granulomas.  
It is already known that skin reactions occur 
with different severity and frequency for each drug.  
Cutaneous EGFRi-induced side effects, 
generally classified as moderate, may become 
chronic, impacting patient’s quality of life and requiring 
therapy reduction or even interruption [23]. As a 
consequence, the appearance of an adverse reaction 
may compromise treatment efficacy and cancer 
response [24]. 
So, we assume that the knowledge and the 
correct management of drug reactions are important 
to prevent their appearance and to avoid unnecessary 
interruption of drugs, especially of those giving a 
higher survival rate to oncological patients. 
The management of cutaneous toxicities in 
lung cancer patients should also include patient and 
family support, self-esteem maintenance and quality 
of life improvement for 360-degree patient care. 
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